Last reviewed · How we verify
NCT05028998: COPE
COVID-19-Related Opioid Treatment Policy Evaluation
trial in Opioid-use Disorder in 110 participants. Status unknown.
27 July 2023
Quick facts
| Lead sponsor | Boston VA Research Institute, Inc. |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 110 |
| Start date | 15 September 2021 |
| Primary completion | 27 July 2023 |
| Estimated completion | 31 August 2023 |
| Sites | 1 location across United States |
Conditions studied
- Opioid-use Disorder — all drugs for Opioid-use Disorder →
- Alcohol Use Disorder — all drugs for Alcohol Use Disorder →
Sponsor
Boston VA Research Institute, Inc.
Who can join
18 and older, any sex, with Opioid-use Disorder or Alcohol Use Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Our nation is facing the COVID-19 pandemic during an ongoing opioid epidemic. Effective treatment for patients with opioid use problems involves a treatment method called Medication-Assisted Treatment, or MAT. In MAT, patients receive a medication that reduces cravings and withdrawal symptoms and can prevent overdose. Patients also receive counseling. Because the medications that are used in MAT are controlled substances, this treatment is subject to a number of federal regulations. The need for social-distancing during the pandemic would have made following these regulations very difficult for patients and their providers. Because of these difficulties, the federal government eased regulations in March 2020, making it easier for patients to receive MAT with fewer (if any) in-person visits for medication and counseling. Our team is studying the effects of these policy changes on the treatment that patients with opioid use disorder receive and on their outcomes. We are using both quantitative analyses of large, existing databases and qualitative analyses of interviews with patients, providers, and policy-makers to study these effects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05028998
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Opioid-use Disorder
Currently open trials in the same condition.
- NCT04783558 — Effective Caregiving for Neonatal Abstinence Syndrome: Testing an Instructional Mobile Technology Platform for High-Risk · NA · active not recruiting
- NCT05011266 — Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder · Phase 2, PHASE3 · recruiting
- NCT05039554 — Randomized Trial of ACT and a Care Management App in Primary Care-based Buprenorphine Treatment · NA · recruiting
- NCT05033028 — Smartphones for Opiate Addiction Recovery · Phase 3 · recruiting
- NCT04738825 — Promoting HIV Risk Reduction Among People Who Inject Drugs: A Stepped Care Approach Using Contingency Management With Pr · NA · recruiting
Other Boston VA Research Institute, Inc. trials
Trials by the same sponsor.
- NCT05800782 — Face Perception vs. Memory Training to Improve Face Recognition in Developmental Prosopagnosia · NA · unknown
- NCT05299749 — Real-time fMRI Neurofeedback in Patients With Schizophrenia and Auditory Hallucinations · NA · recruiting
- NCT04799340 — Computer-based Training of Face Recollection to Improve Face Recognition in Developmental Prosopagnosia · NA · unknown
- NCT04331535 — The Genomic Medicine at VA Study · NA · unknown
- NCT04225130 — Decreasing Suicide Risk Among Service Members With Posttraumatic Stress · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05028998 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Boston VA Research Institute, Inc.
- Last refreshed: 1 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05028998.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing